1. In Vivo
  2. >>Archive

CGT Catapult Builds Cell/Gene Manufacturing Facility

 
• By Peter Charlish

The CTG Catapult aims to capture the commercial potential of the UK's cell and gene therapy research. To that end, it has constructed a GMP-compliant manufacturing facility in Stevenage.

Keith Thompson is not a man to let the grass grow under his feet. Since taking the helm at the UK’s then brand-new Cell and Gene Therapy Catapult in April 2012, the former head of the Scottish National Blood Transfusion Service has made rapid progress in positioning the UK as a global leader in the development, delivery and commercialization of cell and gene therapy.

The cell and gene therapy sector is growing rapidly, Thompson says, with some 16% of all companies in this area...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo